Drug profile · INN
prednisolone
PANAFCORTELONE
prednisolone (PANAFCORTELONE) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — prednisolone
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 103
- Data quality
- 0.89
Quick answer
prednisolone (PANAFCORTELONE) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is prednisolone?
prednisolone (PANAFCORTELONE) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for prednisolone?
PANAFCORTELONE is a marketed brand name for prednisolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prednisolone?
prednisolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.